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In a Dutch consanguineous family with recessively inherited nonsyndromic hearing impairment (HI), homozygosity mapping com-
binedwithwhole-exome sequencing revealed aMPZL2homozygous truncating variant, c.72del (p.Ile24Metfs*22). By screening a cohort
of phenotype-matched subjects and a cohort of HI subjects in whomWES had been performed previously, we identified two additional
families with biallelic truncating variants of MPZL2. Affected individuals demonstrated symmetric, progressive, mild to moderate
sensorineural HI. Onset of HI was in the first decade, and high-frequency hearing was more severely affected. There was no vestibular
involvement. MPZL2 encodes myelin protein zero-like 2, an adhesion molecule that mediates epithelial cell-cell interactions in several
(developing) tissues. Involvement of MPZL2 in hearing was confirmed by audiometric evaluation of Mpzl2-mutant mice. These
displayed early-onset progressive sensorineural HI that was more pronounced in the high frequencies. Histological analysis of adult
mutant mice demonstrated an altered organization of outer hair cells and supporting cells and degeneration of the organ of Corti. In
addition, we observed mild degeneration of spiral ganglion neurons, and this degeneration was most pronounced at the cochlear
base. AlthoughMPZL2 is known to function in cell adhesion in several tissues, no phenotypes other than HI were found to be associated
with MPZL2 defects. This indicates that MPZL2 has a unique function in the inner ear. The present study suggests that deleterious
variants of Mplz2/MPZL2 affect adhesion of the inner-ear epithelium and result in loss of structural integrity of the organ of Corti
and progressive degeneration of hair cells, supporting cells, and spiral ganglion neurons.Introduction
The identification of genes associated with hereditary non-
syndromic hearing impairment (NSHI) has accelerated in
the last decade with the introduction of next-generation
sequencing. But despite the fact that currently more than
100 deafness-associated genes are known (Hereditary Hear-
ing loss Homepage; see Web Resources), more than 60
percent of subjects with hereditary NSHI still cannot be
genetically diagnosed.1–6 These individuals and their
relatives receive suboptimal care because of insufficient
counseling on prognosis and recurrence risk. In addition,
syndromic features can be overlooked, or in the opposite
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 2018 American Society of Human Genetics.tests to screen for additional symptoms that are not
present.
Given the number of deafness loci for which the associ-
ated gene is not known yet (Hereditary Hearing loss
Homepage), it is estimated that many monogenic forms
of NSHI still await identification. Discovery of these
NSHI-associated genes will contribute to the full under-
standing of the complex physiology of hearing. However,
the search for genes associated with deafness has become
more challenging because most frequently involved genes
are already known and those that remain are most likely
involved in less than 1 percent of the cases, or even in
only one or a few families with NSHI. Also, identification
of deleterious variant(s) in a single family in a gene notd University Medical Center, 6500 HB Nijmegen, the Netherlands; 2The
enter, 6500 HB Nijmegen, the Netherlands; 3Donders Institute for Brain,
en, the Netherlands; 4Institute of Biomedical Research ‘‘Alberto Sols,’’ Span-
rid, Spain; 5Center for Biomedical Network Research in Rare Diseases, Insti-
ealth Research, 28029 Madrid, Spain; 7Servicio de Genetica, Hospital Uni-
, Madrid, Spain; 8Department of Neurology, Radboud University Medical
ogy, Department of Laboratory Medicine, Radboud University Medical Cen-
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yet associated with NSHI is insufficient proof for causality.
Functional studies and animal models are important tools
for providing evidence for involvement of the identified
gene in hearing.7,8
In this study, we report the identification of an
NSHI-associated gene, MPZL2 (MIM: 604873), by
combining homozygosity mapping and whole-exome
sequencing (WES) of a family of Dutch origin. Subsequent
screening of a phenotype-matched cohort and analysis of
WES data of genetically undiagnosed individuals with
NSHI led to the identification of two additional families
of Turkish origin with truncating variants in MPZL2. We
characterized the phenotype of affected individuals and
of mice with an intragenic deletion ofMpzl2.9 In addition,
we observed histological abnormalities in the cochleae of
the mutant mice.Subjects and Methods
Subject Evaluation
This study was approved by the medical ethics committee of the
Radboud University Medical Center and is in accordance with
the principles of the World Medical Association Declaration of
Helsinki. Written informed consent was obtained from all
participants or their legal representatives.
Medical history was obtained from all participants via a ques-
tionnaire focusing on hearing and balance, as well as possible
acquired causes of HI. Otoscopy was performed in all subjects so
that the tympanic membrane and aeration of the middle ear could
be assessed. Pure-tone audiometry was performed in a sound-
treated room according to current standards. Air conduction
thresholds were determined at 0.25, 0.5, 1, 2, 4, and 8 kHz in dB
HL. Bone conduction thresholds were determined at 0.5, 1, 2, 4,
and 8 kHz in dB HL, so that conductive HI could be excluded.
HI was described according to the recommendations of the
GENDEAF study group.10 Progression of HI was evaluated by
cross-sectional linear regression analysis of last-visit audiograms
of the better-hearing ear and used for construction of age-related
typical audiograms (ARTAs), as described previously.11 Individual
progression of HI was calculated for each frequency with longitu-
dinal linear regression analyses via GraphPad Prism 6.0. Tympan-
ometry was performed, and click-evoked ABR and otoacoustic
emissions (OAEs) were obtained according to current standards.
Contralateral and ipsilateral acoustic reflexes were measured at
0.5, 1, 2, and 4 kHz up to the loudness discomfort level. Speech-
perception thresholds and maximum speech-recognition scores
were determined with speech audiometry, which was performed
in a sound-treated room with standard monosyllabic consonant-
vowel-consonant Dutch word lists.12
Vestibular function was assessed with electronystagmography
(ENG) rotary chair stimulation and caloric irrigation testing accord-
ing to current standards. Additionally, cervical vestibular evoked
myogenicpotentials (cVEMPs) andvideohead impulse tests (vHITs)
were performed so that sacculus and vestibulo-ocular reflex (VOR)
functionality, respectively, could be assessed. For assessing the pres-
ence of polyneuropathy, standardized neurological screening was
performed in accordancewith a predefined protocol (Supplemental
Methods). Screening for Immunological and corneal defects was
performed as described in the Supplemental Methods.TheDescription of Subject Cohorts
Two cohorts, a phenotype-based cohort and a WES cohort, were
screened for the presence of MPZL2 variants. The phenotype-
based cohort consisted of 120 individuals with a phenotype
comparable to that of individuals of family W05-682, affected
members of which demonstrated sensorineural NSHI and a flat,
cookie-bite or downsloping audiogram configuration. Of these,
57 subjects were Dutch and displayed stable, mild to severe
NSHI; 63 subjects were Spanish and displayed mild to profound
NSHI. Only isolated cases and subjects with suspected auto-
somal-recessive inheritance were included. All subjects were previ-
ously tested for a phenotype-based selection of single genes.
The WES cohort consisted of 270 subjects who had presumed
recessive HI and for whom WES had been performed previously
in a clinical diagnostic setting. In these subjects, pathogenic vari-
ants in genes known to be associated with HI (gene panels DGD
200614, DG2.4x or DG2.5/2.6) were excluded by targeted analysis
of WES data, as described previously.6 Gene lists and coverage in
WES are available at the Genome Diagnostics Radboudumc home-
page (see Web Resources). Variants in genes of the panels were
classified according to the guidelines from the Association for
Clinical Genetic Science and the Dutch Society of Clinical Genetic
Laboratory Specialists.13 Subjects were not preselected on the basis
of their HI phenotype.
Homozygosity Mapping
Genomic DNAwas isolated from peripheral blood lymphocytes by
standard procedures. The samples of subjects II:1 and II:3 of family
W05-682 (Figure 1) were genotyped with the Affymetrix mapping
250K SNP array according to the manufacturer’s protocol (Santa
Clara, CA, USA). Genotype calling was performed with the
Genotyping Console software (Affymetrix) under default settings.
Homozygosity mapping was performed with the online tool
HomozygosityMapper14 so that significant shared homozygous
regions could be identified. Other shared homozygous regions
larger than 1 Mb and regions of shared heterozygous genotypes
were identified manually.
VNTR Marker Analysis
Genotyping of variable number of tandem repeat (VNTR) markers
was performed by DNA amplification with touchdown PCR and
analysis on an ABI Prism 3730 Genetic Analyzer (Applied Bio-
systems). Primers for amplification of VNTR loci were designed
with Primer3Plus. Genetic location of the markers was derived
online from the Marshfield genetic map, and marker order was
confirmed in the human genome assembly GRCh37/hg19. Alleles
were assigned with GeneMapper v.4.0 software according to the
manufacturer’s protocol (Applied Biosystems).
Whole Exome Sequencing
Exome DNA was enriched using the Agilent SureSelect version 4,
5, or 6 kit. WES was performed on an Illumina HiSeq system by
BGI-Europe (Denmark). The index cases of families W05-682,
W16-0195, and W16-0451 were reanalyzed for an updated gene
panel for HI (panel DG2.11) as described in the section ‘‘Descrip-
tion of Subject Cohorts.’’ Copy-number variation (CNV) was
evaluated by depth-of-coverage analysis with CONIFER as
described.15,16 Mean R20x coverage per sample was 95.9% to
96.5% of the enriched regions. Variants were regarded as rare if
the minor-allele frequency (MAF) was%1% in the in-house data-
base of 15,000 exomes and if the MAF was %1% in gnomAD.American Journal of Human Genetics 103, 74–88, July 5, 2018 75
Figure 1. Pedigrees, VNTR Genotypes and Segregation of Variants of MPZL2
(A) Genotypes of VNTR markers and segregation of identified truncating variants ofMPZL2 in family W05-682. BesidesMPZL2, TECTA
(DFNB21) is also located within the homozygous region shared by the affected individuals. Pathogenic variants in the coding and in-
tronic regions of TECTA were excluded.
(B) Pedigrees and segregation analyses of two additional families with deleterious variants inMPZL2. Index cases are indicated by arrows.
Double lines indicate consanguinity (for extended pedigrees, see Figure S1).Prediction of deleterious effects of missense variants and predic-
tion of an effect on splicing were performed as described in the
Supplemental Methods.Sanger Sequencing
Primers for amplification of exons and exon-flanking intronic
sequences of MPZL2 (GenBank: NM_005797.3) and TECTA
(ENST00000392793, MIM: 602574) and primers for mRNA anal-
ysis of TECTA were designed with Primer3Plus and Oligo Primer
Analysis Software. Amplification by PCR was performed under
standard conditions. DNA isolated from peripheral blood samples
was employed for analysis of exons and exon-flanking intronic
DNA of MPZL2 and TECTA. For TECTA mRNA analysis, total
RNA was isolated from Epstein-Barr-virus-transformed lympho-
blastoid cells of affected subjects II:1 and II:3 of family W05-68276 The American Journal of Human Genetics 103, 74–88, July 5, 2018with the NucleoSpin RNA II kit (Machery Nagel) according to
the manufacturer’s protocol. Poly Aþ RNA was isolated from total
RNA with the OligoTEX mRNA Spin Column kit (QIAGEN) ac-
cording to the manufacturer’s protocol. Subsequently, cDNA
synthesis was performed with the iScript cDNA Synthesis Kit
(Bio-Rad Laboratories) and 0.5 mg poly Aþ RNA as a starting
material, according to the manufacturer’s protocol. PCRs were
performed on 2 mL cDNA with Taq DNA polymerase (Roche).
PCR fragments were purified with ExoI/FastAP or ExoSAP-IT
(Thermo Fisher Scientific) in accordance with manufacturers’
protocols. Sequence analysis was performed with the ABI PRISM
BigDye Terminator Cycle Sequencing v.2.0 Ready Reaction kit
and analyzed with the ABI PRISM 3730 DNA analyzer or the
3130 Genetic Analyzer (Applied Biosystems). Possibly deleterious
effects of the identified variants on the MPZL2 and TECTA
proteins and on splicing were predicted with Alamut Visual
(Interactive Biosoftware). Primer sequences and PCR conditions
are provided in Table S1.Quantitative PCR Analysis for Identification of
Intragenic Deletions and Determination of MPZL2
Expression in Human Tissues
Genomic quantitative PCR (qPCR) was performed as described in
the Supplemental Methods. For analysis of transcript levels, total
RNA derived from fetal heart, skeletal muscle, lung, brain, colon,
kidney, stomach, spleen, and thymus and from adult skeletal
muscle, liver, duodenum, stomach, spleen, thymus, and testis
was purchased from Stratagene. Adult heart, lung, brain, kidney,
bone marrow, and placenta total RNA was purchased from
BioChain. In addition, total RNA was isolated from fetal cochlea
(8 weeks of gestation) as described previously.17 Subsequently,
cDNA synthesis was performed with the SuperScript cDNA
Synthesis Kit (Thermo Fisher Scientific) and 2 mg total RNA as
starting material, according to the manufacturer’s protocol. Speci-
fication on primer design, the qPCR system, and reactionmixtures
are indicated above and in the Supplemental Methods. Primer
sequences and conditions are provided in Table S1. The human
beta glucuronidase gene (GUSB, MIM: 611499) was employed as
a reference gene. All reactions were performed in duplicate. Rela-
tive gene expression levels were determined with the delta-delta
Ct method.18Audiometric Characterization of Mpzl2-Mutant Mice
Hearing was evaluated in C57BL6J wild-type (WT) and Mpzl2-
mutant mice.9 In these mutant mice, exons 2 and 3 of Mpzl2
were deleted by standard gene-targeting methods.9 This is pre-
dicted to result in an in-frame deletion of the coding sequences
for amino acid residues 20–145, encompassing part of the signal
sequence and the majority of the extracellular region of the 215
residue MPZL2 protein (cf. Figure S1). The strain was described as
Mpzl2ko/ko, although RT-PCR on liver RNA and Sanger sequencing
of the amplicon confirmed transcript splicing of exon 1 to exon 4
as the only detectable splicing event in the mutant mice (P.S., un-
published data). The presence of the shortened protein in tissues
of the mutant mice remains to be determined.
Auditory brainstem responses (ABRs) were registered in 4-, 8-,
and 12-week-old mice (n ¼ 5 per genotype and age group),
essentially as reported by Cediel et al. (2006)19 with the modifica-
tions reported by Murillo-Cuesta et al. (2015).20 In brief, ABR re-
cordings were obtained under anesthesia with ketamine (75 mg/
kg, Imalgene, Merial) and xylacine (5 mg/kg, Rompun, Bayer).
Click (0.1 ms, 30 pps rate) and tone-burst stimuli (8, 16, 20, 28,
and 40 kHz, 5 ms, 50 pps rate) were generated with SigGenRP soft-
ware (Tucker-Davis Technologies). Stimuli were presented from 90
to 10 dB, relative to sound pressure level (dB SPL) in 5–10 dB SPL
steps with a MF1 speaker (TDT). The electrical responses were
amplified, recorded, and averaged, and hearing thresholds were
determined in the ABR recordings. Amplitudes of ABR waves I,
II, and IV and interpeak latencies of peaks I-II, II-IV, and I-IV
were analyzed for 70 dB SPL click stimuli.
Statistical analysis was performed with IBM SPSS 23.0 software.
Nonparametric Mann-Whitney U tests were used for compaing
ABR parameters between genotypes because of the small sample
sizes. Differences were considered significant if p < 0.05.
Animal experiments were conducted in accordance with Span-
ish and European legislation and approved by the local bioethics
committees.TheHistology and Immunohistochemistry of Cochleae from
Wild-Type and Mpzl2-Mutant Mice
Histology and immunohistochemistry were performed according
to standard protocols, which are detailed in the Supplemental
Methods. Antibodies used were the following: primary antibodies,
rabbit anti-Kir4.1 (AB5818 Chemicon), rat anti-ZO-1 (sc-33725,
Santa Cruz); rabbit anti-KCNQ1 (sc-20816, Santa Cruz), rabbit
anti-Myosin VIIa (25-6790, Proteus), and goat anti-SOX2 (sc-
17320, Santa Cruz). Rabbit anti-MPZL2, raised against the com-
plete protein (11787-1-AP, Proteintech), goat anti-Collagen IV
(1340-01, SouthernBiotech), and mouse anti-Naþ-KþATPase a1
(a6F, Developmental Studies Hybridoma Bank). The following
served as secondary antibodies: Alexa Fluor (AF) conjugated im-
munoglobulins (Molecular Probes): AF 568-goat anti-rabbit
(A11011), AF 488-donkey anti-goat (A11055), AF 488-goat anti-
mouse (A11029), and AF 488-goat anti-rat (A11006).Results
Homozygosity Mapping and WES Revealed Loss-of-
Function Variants of MPZL2
Homozygosity mapping in a Dutch consanguineous fam-
ily in which some members had autosomal-recessive
NSHI (W05-682; Figure 1 and Figure S2) revealed a single
significant homozygous region of 23.8 Mb on chromo-
some 11q23.1-q25, flanked by single-nucleotide polymor-
phisms (SNPs) rs4936310 and rs10458997 (Figure S3).
VNTR marker analysis confirmed homozygosity of the re-
gion, and segregation of marker alleles in the family was
compatible with linkage of the HI with a region that was
flanked by D11S1893 at the centromeric side and included
D11S2359 at the telomeric side (Figure 1A). D11S2359 is
the most telomeric VNTR marker of chromosome 11q
(UCSC Genome Browser, GRCh37/hg19). Combining
VNTR marker and SNP data delimits the critical region to
Chr11: 110,803,280–134,746,130. Two hundred and
nine RefSeq genes, including TECTA, a known deafness-
associated gene, have been annotated in this region
(UCSC Genome Browser, GRCh37/hg19). However, patho-
genic variants in TECTA were excluded by Sanger
sequencing of all exons and exon-intron boundaries and
by mRNA analysis. The homozygous region did not
contain or overlap with any other genes or loci known to
be associated with deafness. Fourteen additional homozy-
gous regions larger than 1 Mb and shared by individuals
II:1 and II:3 were identified (Table S2). There were no
regions with shared heterozygous genotypes larger than
1 Mb.
As a next step, WES was performed in the index case
(II:1) of family W05-682. The mean R20x coverage of
genes in the homozygous region of chromosome
11q23.1–q25 was 98.1%. Variants were filtered as indicated
in Figure S4 and classified as described in the Supplemental
Methods (Table S3). Three rare homozygous variants in
coding sequences and splice sites were present in the
23.8 Mb homozygous region. The BSX (MIM: 611074)
variant c.2635T>C (p.?) (GenBank: NM_001098168.1)American Journal of Human Genetics 103, 74–88, July 5, 2018 77
was predicted not to affect splicing. The missense
GRAMD1B variant c.1111G>A (p.Val371Ile) (GenBank:
NM_001286563.1) was predicted to be pathogenic by
two of the four tools (Table S3). The third variant was a
homozygous one-base-pair MPZL2 deletion, c.72del
(GenBank: NM_005797.3, Figure S5), that is predicted to
result in premature termination of protein synthesis
(p.Ile24Metfs*22). Because MPZL2 was known to be tran-
scribed in the cochlea at a significant level and the variant
was truncating, it seemed the most promising candidate
gene.21,22 The MPZL2 variant c.72del, with a global minor
allele frequency (MAF) of 0.00077 and aMAF of 0.00127 in
the non-Finnish European population, has only been re-
ported heterozygously in gnomAD. The variant is reported
to be most common in Ashkenazi Jews (MAF 0.00375).
Segregation analysis by Sanger sequencing demonstrated
co-segregation of the variant and HI in the family
(Figure 1A), which was also true for the variants of BSX
and GRAMD1B. Targeted analysis of WES data for a panel
of 142 HI-associated genes revealed no other (likely) path-
ogenic variants. Also, no CNVs of the 142 HI-associated
genes were detected, and thus no CNVs of TECTAwere de-
tected either. There were also no CNVs detected in the
23.8 Mb region. Exonic and flanking intronic sequences
of TECTA were fully covered (R15x). All detected variants
of this gene are displayed in Table S4. None of the
homozygous variants that occurred outside of the
23.8 Mb homozygous region and that were predicted to
be pathogenic by two or more prediction tools co-segre-
gated with the disease in the family (Table S3).
Identification of Additional Families with Deleterious
MPZL2 Variants
We addressed further involvement of MPZL2 variants in
recessive NSHI. A phenotype-based cohort of 120 unre-
lated probands with a phenotype similar to that of affected
individuals in family W05-682 was screened for variants of
MPZL2. This revealed the variant c.72del (p.Ile24Metfs*22)
in a homozygous state in a family of Turkish origin,
W16-0195. The variant was present heterozygously
in the unaffected consanguineous parents (Figure 1B,
Figure S5).
In two other individuals of the phenotype-based cohort,
rare heterozygous MPZL2 variants, namely c.268C>T
(p.Arg90Trp) and c.544C>T (p.Arg182*), were identified.
So that possible intragenic deletions of the second allele
could be identified, genomic qPCR was performed for
exons in which no heterozygous SNPs were detected (Table
S5). No deletions were identified. Therefore, defects of
MPZL2 are unlikely to be causative of HI in these subjects.
However, a deleterious variant in non-coding regions of
the gene cannot be excluded.
Subsequently, data of a WES cohort of 270 genetically
undiagnosed NSHI subjects were analyzed for rare MPZL2
variants. This unveiled a third family, W16-0451, that
was of Turkish origin and had truncating variants in
MPZL2. Segregation analysis demonstrated that the78 The American Journal of Human Genetics 103, 74–88, July 5, 2018c.72del and c.220C>T (p.Gln74*) variants were present
in compound heterozygous state in the index case and
that her affected offspring also carried biallelic truncating
MPZL2 variants (Figure 1B, Figure S5). The c.220C>T
variant has been reported only heterozygously in gno-
mAD; it has a global MAF of 0.00038 and an MAF of
0.00003 in the non-Finnish European population, which
represents a significant part of the Turkish ancestry.23
The MAF of c.220C>T is 0.00515 in the East Asian popula-
tion and 0.00016 in the South Asian population, as
indicated in gnomAD. There is admixture of the Turkish
population from Asia, mainly from West and Central
Asia.23 The c.220C>T variant has not been observed in
other populations represented in gnomAD. WES data of
the index case of family W16-0451 were reanalyzed for
the updated panel of 142 HI-associated genes. This analysis
was also performed for WES data of individual II:3. Neither
of the two subjects had any potentially causative variants
or CNVs of these genes and did not share rare CNVs in
the remaining part of the exome. So that other variants
that might underlie HI in family W16-0451 could be iden-
tified, rare variants homozygous in both individual I:2 and
individual II:3 were evaluated, as were potentially com-
pound heterozygous variants (Table S6). Segregation anal-
ysis of the candidate variants predicted to be pathogenic
revealed that only the homozygous PRDM2 (MIM:
601196) variant c.861_863del (GenBank: NM_012231.4;
p.Asp287del) co-segregated with the disease. There were
no variants that were homozygous in individual I:2 or
II:3 and also potentially compound heterozygous in the
other individual. Although the PRDM2 transcript level in
adult human cochlea (FPKM 58-73) is significant and is
comparable to that of MPZL2 (FPKM 35-83),22 no HI has
been reported for homozygous Prdm2-knockout mice
(targeted) in the Mouse Genome Informatics (MGI) data-
base, and ABR measurements of mice with an intragenic
deletion of Prdm2 revealed normal hearing, as reported
by the International Mouse Phenotyping Consortium
(IMPC). Therefore, the variant of PRDM2 is unlikely to
explain the HI in family W16-0451.
The c.72del MPZL2 Variants Are Derived from a
Common Founder
VNTRmarker analysis was performed in familiesW05-682,
W16-0195, and W16-0451 so that the haplotypes in the
MPZL2 region could be determined (Figure S6). All
c.72del MPZL2 alleles shared a haplotype of at least 0.5
Mb, delimited by markers D11S1341 and D11S4104,
suggesting that it is a founder variant rather than a recur-
rent variant due to a mutational hotspot. Because the fam-
ilies have a different ethnic background, the c.72del
variant is likely to be of ancient origin.
Clinical Characterization of Individuals with Pathogenic
Variants of MPZL2
All affected and unaffected subjects of families W05-682,
W16-0195, andW16-0451underwent clinical examinations.
Figure 2. Audiometric Characterization of Families Affected by Pathogenic MPZL2 Variants
(A) Air-conduction thresholds of the better-hearing ear of all affected individuals. The better-hearing ear was determined from
calculations of the mean of the pure-tone thresholds for 0.5, 1, 2, and 4 kHz of the last audiogram. First-visit and last-visit audiograms
are depicted. Subject II:1 of familyW16-0451 was not able to participate in the clinical evaluation; only retrospective data for this subject
were used for analysis. R, right ear; L, left ear.
(B) ARTA (age-related typical audiogram) constructed by cross-sectional linear-regression analysis of last-visit audiograms of all affected
individuals (n ¼ 8).One of the siblings (II:1) of family W16-0451 was not able
to participate in the current clinical evaluation; only retro-
spective data of this subject were used for analysis. History
revealed that this individual previously underwent surgery
for cholesteatoma of the left ear. Therefore, audiometric
data of the right ear only were used for this study, and these
data showed pure sensorineural HI. However, she also had
osteogenesis imperfecta, which might contribute to her
sensorineural HI. Nevertheless, her hearing thresholds were
very similar to age-matched hearing thresholds of other
affected familymembers, and thereforewedecided to include
her in the audiometric evaluations.
None of the affected subjects (family W05-682, II:1, II:3,
and III:2; family W16-0195, II:1; family W16-0451, I:2,
II:1, II:2, and II:3) demonstrated abnormalities on oto-
scopy and tympanometry (Table S7). Pure-tone audiom-
etry of these individuals revealed no signs of conductive
HI but did demonstrate a symmetric mild to moderate HI
with a gently downsloping audiogram configuration forTheall of them (Figure 2A). The mean reported onset age of
HI was 4 years (min–max: 3–9 years) (Table S8). Four
affected individuals had a disturbed speech-language
development, whereas development was normal in three
cases and unknown in one case. Speech perception thresh-
olds were lower than the pure-tone average thresholds at
0.5, 1, and 2 kHz, andmaximum speech-recognition scores
were 90%–100% for the better-hearing ear, both suggesting
absence of retrocochlear pathology. Acoustic reflexes were
present (both ipsilateral and contralateral) without decay,
which also suggested an absence of retrocochlear pathol-
ogy. OAEs could only be detected in individuals II:2
and II:3 of family W16-0451, for frequencies with
hearing thresholds lower than 30 dB HL. This is indicative
of residual function of cochlear OHCs.24 OAEs were
absent in all other affected subjects. The index cases of
families W05-682 and W16-0195 displayed normal ABR
wave latencies, which indicated normal auditory neural
processing. Additional information on otologic andAmerican Journal of Human Genetics 103, 74–88, July 5, 2018 79
audiometric evaluation of individual cases is provided in
Table S7.
Individual longitudinal regression analyses of hearing
thresholds revealed that HI was progressive in all affected
adults. No progression could be demonstrated in the
affected children, for whom follow-up time (1–11 years)
was probably too short for significant progression to be
established. Cross-sectional linear-regression analysis
revealed progression of HI for all frequencies. The
increase of hearing thresholds was significant at 1 kHz
(0.8 dB/year), 2 kHz (0.5 dB/year), and 4 kHz (0.6 dB/year).
In Figure 2B, the ARTA is depicted, which demonstrates
gradual progression of HI.
None of the affected subjects or their parents reported
vestibular symptoms, such as vertigo, dizziness, instability,
or delayed motor development, except for the index case
of family W16-0451 (I:2), who reported two periods of ver-
tigo in the past without persisting complaints. Vestibular
function was assessed in three of the hearing-impaired in-
dividuals (family W05-682, II:1; family W16-0451, I:2 and
II:2), and normal to slightly hyperreactive vestibular re-
sponses were measured (Table S8).
Because MPZL2 is highly homologous to MPZ (MIM:
159440), which is associated with distinct types of heredi-
tary motor and sensory neuropathy,25–31 we performed
neurological screening of the affected individuals (family
W05-682, II:1, II:3, and III:2; family W16-0195, II:1; and
familyW16-0451, I:2, II:2, and II:3). No symptoms or signs
of neuropathy were present.
Hearing-impaired subjects were also screened for immu-
nological abnormalities becauseMPZL2 is involved in early
thymocyte development.32–34 None of them had
symptoms of immunodeficiency, allergies, or autoimmune
disease. CD4 and CD8 T cell counts, including double-pos-
itive (CD4þCD8þ) and double-negative (CD4CD8) cell
counts, as well as the CD4/CD8 ratios, were normal
(Figure S7), indicating normal CD4 and CD8 expression
on T cells.
Because gene expression studies have shown thatMPZL2
transcript levels are relatively high in the cornea of the eye
(Ocular Tissue Database),35 affected individuals were
screened for corneal abnormalities. There were no eye
problems, slit lamp biomicroscopy did not show abnor-
malities, and visual acuity was normal.
MPZL2 Is Expressed in Human Fetal Cochlea
The relative expression of MPZL2 was determined in hu-
man fetal cochlea and various other fetal and adult human
tissues (Figure S8). Because the fetal tissues were not
derived from embryos of the same gestational age, mRNA
transcript levels are not directly comparable. Among the
tested fetal tissues, MPZL2 expression was highest in the
inner ear, where transcript levels were 70-fold higher
than in skeletal muscle, which displayed the lowest detect-
able expression. Also, in all other fetal tissues MPZL2
transcript levels were significantly lower than those in
the inner ear. In the analysis ofMPZL2 expression in adult80 The American Journal of Human Genetics 103, 74–88, July 5, 2018tissues, mRNA levels of MPZL2 in the fetal inner ear were
included for comparison. MPZL2 mRNA was detected in
all analyzed adult tissues, and the highest levels were in
the thymus and lung, whose levels were in the range of
those in fetal inner ear.
Mpzl2-Mutant Mice Are Hearing Impaired
Mpzl2-mutant mice showed early-onset progressive HI and
significantly increased ABR thresholds in response to click
and tone-burst stimuli in the ages studied, when these
mice were compared to age-matched C57BL6J, normal-
hearing wild-type mice. Four-week-old mutant mice
showed a mild HI that affected the detection of click
stimuli and pure-tone frequencies above 16 kHz (Figures
3A and 3B) at statistically significant higher thresholds
(p < 0.05) than for wild-type mice. HI in mutant mice
rapidly progressed to moderate and severe at the ages of
8 and 12 weeks, respectively, and these mice had statisti-
cally significant elevated thresholds for all tested stimuli
in comparison to wild-type mice. At 12 weeks of age,
ABR thresholds in response to 16–40 kHz are above
70 dB SPL in the mutant mice, whereas wild-type mice
maintained normal hearing at thresholds below 30 dB
SPL. Accordingly, significant alterations in ABR peak am-
plitudes, latencies, and interpeak latencies were observed
in mutant mice. The maximum amplitudes of wave I,
which represents cochlear activity, were approximately
30% lower in the knock-out animals than in the wild-
type mice at all ages studied (Figure 3C), and differences
reached significance in 4-week-old mice (Figure 3D). In
addition, wave I peaks showed increased latencies in the
mutants as compared to wild-type mice, which progressed
over time. Peaks were increased in young animals (4 weeks
old) at the level of intensity near the threshold, whereas
in 12-week-old mice they were increased for all intensities
tested (Figure 3E). Also, mutant mice showed significantly
shorter interpeak latencies (IPLs) I-II, II-IV, and I-IV than
wild-type mice (Figure 3F). These data suggest a compensa-
tory central response to the delayed peripheral transmis-
sion, as already shown in the Igf1 knockout.36
Mpzl2-Mutant Mice Display Alterations in Cell
Organization and Cell Loss in the Organ of Corti
We evaluated the general cochlear cytoarchitecture in the
basal, medial, and apical turns of the cochlea of 12-week-
old mice (Figure 4 and Figure S9) to assess the integrity of
the principal structures. Namely, we looked at the organ
of Corti with inner and outer hair cells (IHCs and OHCs,
respectively) responsible, respectively, for the mechano-
transduction and amplification and tuning of the sound,
and we looked at different types of supporting cells.
Furthermore, we evaluated the spiral ganglion neurons
that connect the hair cells with the central auditory
pathway; the stria vascularis, involved in the formation
of the high-potassium-containing endolymph, in the
lateral wall; and the spiral ligament. Loss of hair and
supporting cells of the organ of Corti (asterisk in
Figure 3. Hearing Phenotype of Mpzl2-
Mutant (Mpzl2ko/ko) Mice
(A) Representative click-evoked ABR re-
cordings at decreasing intensities (dB SPL)
in 4-, 8-, and 12-week-old wild-type and
Mpzl2-mutant mice. Waves are labeled
I–IV and reflect the evoked activity of the
auditory nerve (I) and ascending points
of the auditory pathway in the midbrain
(II–IV). As the stimulus level is reduced,
amplitudes of ABR waves decrease and
latencies of waves increase. The lowest in-
tensity at which the ABR-wave profile is
higher than the background-noise signal
is the threshold (bold line; WT, blue;
Mpzl2-mutant mice, green).
(B) ABR thresholds, in response to click
and 8–40 kHz tone bursts, of the different
genotypes and age groups.
(C and E) ABR wave I amplitude/intensity
(C) and latency/intensity (E) curves in
response to click stimuli of increasing
intensities were determined in 4- and 12-
week-old wild-type and Mpzl2-mutant
mice.
(D and F) Peak amplitude of ABR waves I,
II, and IV (D) and interpeak latencies I-II,
II-IV, and I-IV (F) in response to a 70 dB
SPL click stimulus in 4- and 12-week-old
wild-type and Mpzl2-mutant mice. Data
are shown as means5 SEM. Statistical sig-
nificance: *p < 0.05; **p < 0.01.Figure S9D) and of neurons in the spiral ganglion (asterisks
in Figure S9D-1) were observed in the basal cochlear turn of
mutants, but not in wild-type mice. No evident structural
abnormalities were seen in the stria vascularis or spiral lig-
ament. Markers of the stria vascularis were not altered in
mutant mice, as compared to age-matched wild-type ani-
mals (Figure S10).
A closer evaluation of the organ of Corti (Figure 4)
showed clear differences between wild-type and Mpzl2-The American Journal of Humutant mice at 12 weeks of age. At
the basal turn of the cochlea, two
mutant mice showed a flat epithe-
lium at the basilar membrane; there
was complete loss of hair and sup-
porting cells (asterisks in Figure 4N
and Figure 4O). At themedial and api-
cal turns of the cochlea, hair and
supporting cells were present in both
genotypes, as were tunnel-forming in-
ner and outer pillar cells (IPs and OPs,
respectively) (Figure 4E). However,
mutant mice showed an aberrant
mosaic pattern of OHCs and support-
ing Deiters’ cells (DCs; the spaces
between OHCs had collapsed, and
DC nuclei were displaced with respect
to OHCnuclei (asterisks in Figures 4G,
4H, 4J–4L, and 4P).Specific immunolabeling for Myosin VIIa and SOX2
evidenced that IHCs, OHCs, and supporting cells were
present. Also, this analysis confirmed that mutant mice
display a disorganized arrangement of OHCs and DCs in
the apical (asterisks in Figures 5B and 5C) and middle
(asterisk in Figure 5H) turns and that they display
decreased numbers or an absence of all cell types in the
basal turn of the cochlea (asterisks in Figures 5J–5L), in
comparison to wild-type mice. Statistically significantman Genetics 103, 74–88, July 5, 2018 81
Figure 4. Cochlear Morphology of
12-Week-Old Wild-Type and Mpzl2-
Mutant (Mpzl2ko/ko) Mice
Microphotographs show representative
midmodiolar cross sections of the cochlea
from one representative wild-type mouse
(A) and three Mpzl2-mutant mice (B–D).
The apical (a), middle (m), and basal (b)
organs of Corti are boxed in image (A).
Close-ups of the organ of Corti from one
wild-type mouse (E, I, and M) and three
Mpzl2-mutant mice (F–H, J–L, and N–P)
are shown. Arrowheads point to inner
hair cells (IHCs), blackhead arrows to outer
hair cells (OHCs), and arrows to Deiters
cells (DCs). BM, basilar membrane; IP,
inner pillar cell; and OP, outer pillar cell.
Asterisks mark abnormalities. The scale
bars represent 500 mm (A–D) and 25 mm
(E–P).differences were found in the number of OHCs in the basal
turn only because of the differences in severity of the
phenotype in mutant mice (Figure S11). At P4, no indica-
tions were obtained for an abnormal cellular organization
in the developing organ of Corti (Figure S12).Mouse MPZL2 Is Present in the Organ of Corti and the
Stria Vascularis
Cochlear expression and localizationofMPZL2was assessed
in wild-type mice at P4 by immunofluorescence, which re-
vealed a signal in DCs and, most intensely, in the basal re-
gion of DCs in all three cochlear turns (Figure 6A and
Figure S13). Staining of serial sections with anti-collagen
IV suggests that MPZL2 is present where DCs contact the
basilar membrane (Figures 6A and 6B). Weaker MPZL2 im-
munostaining is observed in both IHCs and OHCs
(Figure 6A and Figure S13). In the stria vascularis, MPZL2
was detected in the basal cell layer, as confirmed by co-stain-
ing with anti-Naþ-KþATPase, which demarcates the inter-
mediate cell layer (Figures 6C and 6D). Specificity of the
anti-MPZL2 antibodywas confirmed by analysis of cochleae
ofMpzl2-mutantmice in the same experiments (Figure S13).Discussion
This study provides evidence for the association of bial-
lelic defects of MPZL2 with recessively inherited sensori-82 The American Journal of Human Genetics 103, 74–88, July 5, 2018neural NSHI in humans and mice.
Affected human subjects displayed
moderate to severe, slowly progres-
sive HI from the first decade onward,
and intrafamilial and interfamilial
phenotypic similarity was high. The
functional and morphological inner-
ear defects in Mpzl2-mutant mice
provide important evidence for the
causal relationship between MPZL2defects and HI in the studied families. This is further
strengthened by the fact that HI of Mpzl2-mutant mice
and affected family members was similar with regard to
the early onset, the progressive nature, and the fact that
high-frequency hearing was more severely affected than
middle- or low-frequency hearing. The latter is reflected
by the decreasing severity of disorganization and loss of
OHCs and DCs from the cochlear base to apex.37 For
other genes that harbored variants that co-segregated
with HI in families W05-682 and W16-0451 and were pre-
dicted to affect protein function, there are no supporting
data for an association with HI. For GRAMD1B (W05-682),
which is transcribed in adult human cochlea (FPKM 2.09-
8.4422), no phenotyping information on mouse mutants
is available in IMPC or MGI databases. No interactions
of GRAMD1B with proteins encoded by genes associated
with NSHI are reported (STRING or BioGRID).
TECTA (DFNB21, MIM: 603629) was located in the
homozygous candidate region of family W05-682. Reces-
sively inherited defects of TECTA can cause moderate-to-
severe HI, although with a more flat audiogram configura-
tion than observed in the presented families.38,39 We
scrutinized TECTA for defects in family W05-682, and we
excluded (potentially) causative variants in the exonic
sequences and splice sites of the gene. We did not
obtain any indication for aberrant splicing that might
result from deep intronic variants. Only variants in up-
stream or downstream sequences with a regulatory role
Figure 5. Organ-of-Corti Cytoarchitec-
ture of Wild-Type and Mpzl2-Mutant
(Mpzl2ko/ko) Mice
Close-ups of the organ of Corti from repre-
sentative frozen sections (10 mm) prepared
from one representative wild-type mouse
(A, E, and I) and three Mpzl2-mutant
mice (B–D, F–H, and J–L). Hair cells and
supporting cells were immunolabeled for
Myosin VIIa (green) and SOX2 (red),
respectively, in the apical, middle, and
basal turns of the cochlea. Actin in the or-
gan of Corti was stained with phalloidin
(purple). Arrowheads point to inner hair
cells (IHCs), whitehead arrows to outer
hair cells (OHCs), and arrows to Deiters
cells (DCs). Asterisks mark abnormalities.
The scale bar represents 10 mm.in transcription or intronic variants that could cause aber-
rant splicing specifically in the inner ear could have been
missed.
The identified MPLZ2 variants are the most common
truncating variants in the gene; they have the highest
gnomAD allele frequencies, of 0.0051 for c.220C>T in
the East Asian population and 0.00375 for c.72del in the
Ashkenazi Jews. For comparison, the c.2299delG founder
mutation of USH2A (MIM: 608400) is most common in
the latino population (0.0016) and has an allele frequency
of 0.001 in non-Finnish Europeans. The most common
cause of severe autosomal-recessive NSHI, the c.35delG
mutation of GJB2 (MIM: 121011), has a frequency of
0.0097 in non-Finnish Europeans in GnomAD. In light
of this, the identification of defects of MPZL2 as a cause
of HI only now is surprising because the identified defects
are expected to be important causes of HI in East Asia and
in the Ashkenazi Jewish communities. Because research
efforts were concentrated on severe-to-profound early-
onset HI for many years, the association of MPZL2 with
HI might have remained undetected because of the mild-
to-moderate severity of the HI. Also, because of the rela-
tively mild HI, families might have a lower tendency to
consult a genetic counselor or to participate in genetic
studies than families in which more severe HI occurs.
Furthermore, although not supported by our findings in
the presented families, variants of MPZL2 might have a
reduced penetrance that could result from (common)
modifying genetic variants.
The pLI score40 ofMPZL2 is 0.00, which suggests that the
gene is tolerant to loss-of-function variation. This is true
for many of the HI-associated genes, e.g., MYO7A
(MIM: 276903) and USH2A, which have the same pLI score
of 0.00. The tool DOMINO41 predicts thatMPZL2 is associ-The American Journal of Huated with a recessive rather than a
dominant disorder, which is in agree-
ment with our findings.
OHCs function as cochlear ampli-
fiers that enhance hearing thresholds
by more than 40 dB, and loss of theamplifying function leads to 40–60 dB HI.42,43 Because
subjects with deleterious MPZL2 variants displayed a
35–65 dB increase of hearing thresholds, the HI phenotype
is compatible with predominant loss of OHCs. In addition,
the remarkably good speech discrimination compared to
the hearing thresholds and absence of OAEs in the affected
individuals indicate abnormal OHC function.44,45 Given
the only moderate HI of the affected adult subjects of fam-
ily W05-682 and subject I:2 of family W16-0451 at the age
of about 40 years, we hypothesize that IHCs do not degen-
erate over time or that they do so very slowly.
MPZL2 (myelin protein zero-like 2), alternatively called
EVA1 (epithelial V-like antigen 1), is a low-affinity adhe-
sion molecule and a member of the immunoglobulin
superfamily, more specifically of the family of immuno-
globulin-like cell-adhesion molecules (Ig-CAMs).32
Ig-CAMs form a large family of cell-surface molecules
broadly expressed in, for example, epithelial and endothe-
lial cells and in the nervous system. Ig-CAMs are known to
interact directly with other classes of cell-surface mole-
cules, such as cadherins, integrins, and tyrosine kinase
receptors, and intracellularly they interact with cytoskel-
eton proteins such as actin and ankyrin (for review,
see46,47).
The biological function of MPZL2 is likely to be related
to its ability to mediate both homophilic and heterophilic
cell-cell adhesions. In mice, Mpzl2 is already expressed
early in embryogenesis in various epithelial tissues as
well as in adult tissues.32,48 An adhesive function of
MPZL2 has been indicated in thymus histogenesis and
T cell development,32,33 placental morphogenesis,49 the
blood-cerebrospinal barrier,50 lymphocyte adhesion to
choroid plexus epithelial cells,51 and mammary epithe-
lial-cell differentiation.48 Upregulation of Mpzl2 inman Genetics 103, 74–88, July 5, 2018 83
Figure 6. MPZL2 Displayed a Distinct
Localization in the Cochlear Organ of
Corti and Stria Vascularis at P4 in Wild-
Type Mice
(A) MPZL2 (red) localizes in the organ of
Corti in the basal region of Deiters cells
(DCs) present below the three rows of outer
hair cells (OHCs) and diffusely in inner
hair cells (IHCs), OHCs, and DCs.
(B) In a serial section, collagen IV (green)
immunostaining marked basement mem-
branes, including the basilar membrane
(BM), thereby indicating the localization
of MPZL2 at the DC-BM contact region.
(C) In the stria vascularis, MPZL2 (red) im-
munostaining was observed predomi-
nantly in the basal cell (BC) region.
(D) Co-immunostaining of MPZL2 and
Naþ-KþATPase (green), a marker for mar-
ginal cells (MCs), confirms immunostain-
ing of MPZL2 (red) in the basal cells. Cell
nuclei were stained with DAPI (blue).
Arrowheads point to IHC, whitehead ar-
rows to OHCs, and arrows to DCs. The
scale bar (A–D) repsresents 20 mm.spermatogenic cells of mice deficient in cell-adhesion
molecule 1 further supports the cell-adhesive function.52
Also, MPZL2 was demonstrated to function in the prolifer-
ation and tumorigenesis of glioblastoma-initiating cells53
Despite these manifold indications of functional signifi-
cance of MPZL2, no phenotypes other than HI were re-
ported to be associated with MPZL2 deficiency.53,54 This
suggests thatMPZL2 function is essential only in the inner
ear and that functional redundancy might well prohibit
phenotypic effects in other tissues. This is similar to what
is found for several other HI-assciated genes, e.g., KITLG
and SMPX.7,55 However, more phenotypic effects might
emerge under stress conditions, as is suggested by
increased severity of experimentally induced autoimmune
encephalomyelitis and white-matter tissue injury in
MPZL2-deficient mice.54
In the developing and adult inner ear, several CAMs,
belonging to different protein families, including the
Ig-CAM superfamily, display a specific spatiotemporal
pattern of expression, and several of these Ig-CAMs are
critical for hearing and/or balance in both mice and hu-
mans.56–63 The Ig-CAMs nectin-1 and -3, for example, are
critical for establishing the checkerboard-like organization
of hair cells and supporting cells in the cochlea.64 The
abnormal organization of DCs and OHCs, and their loss
in Mpzl2-mutant mice at 12 weeks of age indicates that
MPZL2 is essential for maintenance of the DC-OHC orga-
nization and integrity. A role in maintenance is supported
by themoderate transcript levels ofMPZL2 in adult human
cochleae.22
Although no structural abnormalities were detected in
cochleae of Mpzl2mutants at P4, MPZL2 is likely to func-
tion in prenatal cochlear development as well, in both84 The American Journal of Human Genetics 103, 74–88, July 5, 2018mice and humans, as indicated by the finding that tran-
scription of the gene was demonstrated in human em-
bryos at 8 weeks of gestation and in mouse developing
hair cells and their surrounding cells from embryonic
day 16 (E16) to P16.65 (See also the SHIELD database.)
From the present study it is unclear whether MPZL2-
associated HI is congenital or has an early-childhood
onset. The fact that speech language development was
disturbed in a number of cases indicates that onset of
HI was prelingual in these individuals. If HI was congen-
ital in the cases with prelingual HI, thresholds were
below 35 dB HL because two of three individuals
with prelingual HI passed a neonatal hearing screening.
These tests are calibrated to pick up HI of more than
35 dB HL.66
We foundMPZL2 to be a CAM that is present specifically
at the base of DCs where they contact the basilar mem-
brane. DCs develop a narrow infranuclear region that
ends in feet-like junctions with the basal membrane.67
The stripe-shaped signal in DCs in MPZL2 immunohisto-
chemistry might represent the developing feet-like struc-
tures. It is tempting to speculate that MPZL2 is involved
in themorphogenesis and/ormaintenanceof the character-
istic structure of DCs by anchoring the actin-rich cytoskel-
etal core of the feet-like structures or the surrounding
microtubules to the basilar membrane.67 The relatively
weak MPZL2 signal in immunohistochemistry at P4 in
OHCs, IHCs, and the cytoplasm of DCs suggests that
MPLZ2 (transiently) functions in homophilic or hetero-
philic cellular junctions of these cells and that absence of
these junctions in Mpzl2-mutant mice might contribute
to the disorganization and degeneration of the organ of
Corti.
Although not much is known about the adhesive
function of MPZL2 at the molecular level, some hints
toward molecular interactions have been obtained. A
co-association of MPZL2 and CLCA2 with tight junction
protein ZO-1 has been described.48 ZO-1 is an adaptor
protein that functions in the coupling of TJs and adherens
junctions (AJs) to the cytoskeleton.68 Also, ZO-1 binds
directly to occludin in vitro.62 Interestingly, an association
of MPZL2 and occludin has been observed in a high-
throughput human protein interaction study.69 Occludin
is a tight-junction (TJ) protein essential for functional
integrity of the reticular lamina of the organ of Corti.60
The organ of Corti of Occ/ mice degenerates, starting in
the OHC region. Because of these associations and the
defects in the organ of Corti in Mpzl2-mutant mice, it is
tempting to speculate that MPZL2 is essential for (func-
tional) integrity of cell junctions in the reticular lamina,
especially in the OHC region, and thereby for ion homeo-
stasis in the cochlea. The associations of MPZL2 with TJ
and AJ proteins and their co-function in the cochlea
have to be validated with other protein-interaction assays,
as well as co-localization assays in the inner ear. The latter
assays were impaired by the failure of antibodies to detect
MPZL2 in the experimental conditions to be used in
immunofluorescence of adult cochleae.
Recently, it was demonstrated that MPZL2 can activate
the NF-kB signaling pathway, most likely by binding
TRAF2, for which a consensus binding site is present in
the cytoplasmic domain of MPLZ2.53 This pathway was
indicated to be protective for hair cell loss by environ-
mental factors such as noise and aminoglycosides.70,71
Therefore, defects of MPZL2 might lead to an increased
sensitivity to noise and other environmental cues.
Although MPZL2 was detected in the basal cell layer of
the developing stria vascularis, no gross histological abnor-
malities were observed in this region of the cochlea in
Mpzl2-mutant mice, either at the age of 4 days or at
12 weeks of age. However, this does not fully exclude func-
tional defects. A mild loss of spiral ganglion neurons was
observed in the basal turn of the cochlea ofMpzl2mutants;
this loss might have been secondary to hair-cell loss.
In conclusion, we demonstrated that MPZL2 is essential
for normal cochlear function in humans and mice. In the
latter species, defects of MPZL2 resulted in OHC and DC
disorganization that is likely to interfere with mechanical
and other functional properties of that region of the
cochlea and ultimately in a loss of integrity of the organ
of Corti. Humans affected by biallelic truncating MPZL2
variants displayed slowly progressive NSHI, which is
important in (genetic) counseling of subjects and their
families.Supplemental Data
Supplemental Data include Supplemental Methods, 13 figures,
and seven tables and can be found with this article online at
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